SHARES:ML proves that bio is still a buy
Sunday 03 November 1996
The food sector has hardly been the place to have your money invested over the last year - as one wag pointed out, it's not so much a case of picking the winners, as avoiding the losers. Perkins Food at least shows some faith in its future prospects, with a 1-for-6 rights issue for pounds 15.5m, to buy the Dutch Disselkoen Group. The attraction to Perkins is that the business, one of the largest fresh food exporters from the Netherlands, gives it instant access to Germany, including a toehold in the country's supermarket chains. With European borders disappearing, the deal should shore up the group's competitive position, while it can also sell its own fresh produce into Disselkoen. Although the Dutch group's margins are, like most fresh-produce suppliers', razor thin, the deal should be earnings neutral in 1997. While the shares, at 81.5p, are making a gradual recovery from the setbacks of 1992, now seems the time for a more whole- hearted commitment. Buy.
More food. If Perkins has yet to fully regain the confidence of investors, that old warhorse Associated British Foods (417p), continues to keep pace with the market. While the business rarely dazzles, nor does it let down shareholders. Tomorrow, it posts its final figures for 1996. Operating profit should come in at around pounds 378m, a gain of 13 per cent, with sales of pounds 5.64bn, up 15 per cent. The shares remain a buy.
A company that is listed over there - on Nasdaq, to be precise - is obtaining a listing over here. Through a placing on the London Stock Exchange, Xenova Group, the UK-based biotech company that develops drugs from natural micro-organisms, hopes to raise pounds 25m. Its first product should be ready for market by 2000. The XR5000 anti-cancer drug should enter clinical trials early next year. Other products include XR9051, to overcome multidrug resistance in cancer chemotherapy, with up to a pounds 1.4bn market. It also has tie-ins to Genentech, Genzyme and Warner-Lambert. Listing details will be published later this month, but the company has some exciting products, and could be worth following.
Tough times at car dealer Evans Halshaw, which announced it was closing a fifth of its dealerships, and taking a pounds 19.8m restructuring charge. To add to its woes, the group said August and September had been difficult for trading, with a consequent impact on full-year results. Although the shares were off only 5.5p, to 248.5p, the prospects are mixed. While the intention is to improve the return on capital, clearly the business is lagging behind its competitors, who have stolen a lead on it in many areas. EH professes it wants to build up its presence "in the larger conurbations, like Birmingham, Leicester and Sheffield". But there, of course, is where the competition is fiercest - although volumes, for successful sites, are far higher. That said, the final impact on full-year results could even be neutral, given the benefit of margin enhancement from the restructuring. Nevertheless, there are better value shares elsewhere in the sector. Sell.
And why are 'southern' ways of speaking spreading north?
life + styleClarissa Baldwin is the brains behind the slogan 'A Dog is for Life not just for Christmas'
Autumn Statement 2013: Work until you’re 70 - George Osborne accused of ‘living in fantasy land’ over pension reforms
Is this the scariest advert ever? Japanese tyre commercial comes with its own disclaimer and health warning
Paul Walker autopsy: Results reveal Fast and Furious star's cause of death
Scientists sequence oldest human DNA from fossilised leg bone found in Spain
UK weather: Two dead and 100,000 homes without power as 100mph storm batters Scotland – now biggest tidal surge in 60 years threatens east coast
- 1 Is this the scariest advert ever? Japanese tyre commercial comes with its own disclaimer and health warning
- 2 How black gold was hijacked: North sea oil and the betrayal of Scotland
- 3 A forgotten episode in Russian history leaves links with the Philippines
- 4 Scientists sequence oldest human DNA from fossilised leg bone found in Spain
- 5 ‘Put it in my mouth’: Viewers outraged by apparent reference to oral sex in VIP e-cig advert
iJobs Money & Business
£75000 - £85000 per annum + Bonus and Benefits: Harrington Starr: An award win...
£90000 - £120000 per annum: Harrington Starr: Global Director of Infrastructur...
£50000 - £70000 per annum + Bonus + Benefits: Harrington Starr: Associate Dire...
£Negotiable: Citifocus: High calibre individual with a strong understanding o...